- Home
- WKC vs MLTX Comparison
WKC vs MLTX Comparison
Compare WKC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WKC | MLTX |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WKC | MLTX |
|---|---|---|
| Price | $36.54 | $10.75 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $37.67 | $28.54 |
| AVG Volume (30 Days) | 848.4K | ★ 1.9M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $36,916,600,000.00 | N/A |
| Revenue This Year | $27.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.21 | $8.80 |
| 52 Week High | $41.20 | $23.29 |
Technical Indicators
Market Signals| Indicator | WKC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 29.80 |
| Support Level | $34.85 | N/A |
| Resistance Level | $37.88 | $19.24 |
| Average True Range (ATR) | 0.86 | 0.66 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 66.33 | 20.60 |
Price Performance
Historical ComparisonAbout WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.